Glass formulations and uses thereof
AssigneeRipple Therapeutics Corporation
InventorsIan Charles Parrag, Matthew Alexander John Statham, Kyle Battiston, Dimitra Louka, Hans Christian Fischer, J. Paul Santerre, Wendy Alison Naimark
Life of this patent
Estimating the term…
Abstract
The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.
Claims29
An article comprising a compound of formula (A-VIII):
- D1-L-D2 (A-VIII)
- or a pharmaceutically acceptable salt thereof, wherein
- (i) each of D1 and D2 is, independently, a radical formed from a steroid;
- and L is a linker covalently linking D1 to D2,
- (ii) at least 70% (w/w) of the article is the compound of formula (A-VIII),
- (iii) the article is free of controlled release polymer and comprises the compound in amorphous form, and
- (iv) the article is a fiber, pellet, cylinder, hollow tube, microparticle, or a nanoparticle.
A method of treating an inflammatory disease or condition in a subject in need thereof, the method comprising administering to the subject an article in an amount sufficient to treat the inflammatory disease or disorder in the subject, wherein the article comprises a compound of formula (A-VIII):
- D1-L-D2 (A-VIII)
- or a pharmaceutically acceptable salt thereof, wherein
- (i) each of D1 and D2 is, independently, a radical formed from a steroid;
- and L is a linker covalently linking D1 to D2,
- (ii) at least 70% (w/w) of the article is the compound of formula (A-VIII),
- (iii) the article is free of controlled release polymer, and comprises the compound in amorphous form.
Dependencies are inferred from the claim text.